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S U M M A R Y
Background: HIV infection increases measles susceptibility in infants, but little is known about this
relationship among older children and adults. We conducted a facility-based study to explore whether
HIV status and/or CD4 count were associated with either measles seroprotection and/or measles
antibody concentration.
Methods: A convenience sample was recruited comprising HIV-infected patients presenting for follow-
up care, and HIV-uninfected individuals presenting for HIV testing at Chiradzulu District Hospital,
Malawi, from January to September 2012. We recorded age, sex, and reported measles vaccination and
infection history. Blood samples were taken to determine the CD4 count and measles antibody
concentration.
Results: One thousand nine hundred and thirty-ﬁve participants were recruited (1434 HIV-infected and
501 HIV-uninfected). The majority of adults and approximately half the children were seroprotected
against measles, with lower odds among HIV-infected children (adjusted odds ratio 0.27, 95% conﬁdence
interval 0.10–0.69; p = 0.006), but not adults. Among HIV-infected participants, neither CD4 count
(p = 0.16) nor time on antiretroviral therapy (p = 0.25) were associated with measles antibody
concentration, while older age (p < 0.001) and female sex (p < 0.001) were independently associated
with this measure.
Conclusions: We found no evidence that HIV infection contributes to the risk of measles infection among
adults, but HIV-infected children (including at ages older than previously reported), were less likely to be
seroprotected in this sample.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Enormous progress towards measles control and elimination
has been made in recent years, due largely to sustained efforts to
increase vaccination coverage among children worldwide with a
cheap, safe, and highly efﬁcacious vaccine.1–3 As a result, measles
incidence and mortality in Sub-Saharan Africa decreased by* Corresponding author. Tel.: +41 (0)22 791 12 96.
E-mail address: jonathan.polonsky@epicentre.msf.org (J.A. Polonsky).
http://dx.doi.org/10.1016/j.ijid.2014.12.010
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).approximately 90% between 2000 and 2010.2,4,5 However, out-
breaks continue to occur in areas where high vaccination coverage
has not been achieved or maintained.3,6–8 For example, in Malawi,
following a reduction from 162 000 measles cases in 1980 to fewer
than 200 per year between 2005 and 2009, a large outbreak
occurred in 2010, with a reported 134 039 cases and 304 deaths.8
Although measles is typically a disease of young children (those
aged less than 5 years),6 an unexpected feature of this Malawian
outbreak was that the majority of cases occurred among
individuals aged 5 years and older, with 28% of cases among
those aged 15 years and older.8 A similar age distribution has beenciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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Africa.5,7,9
There are several possible explanations for this phenomenon,
including low vaccination coverage in subpopulations despite high
national coverage,10 extensive vaccine failure (possibly due to the
logistical difﬁculties of maintaining a functioning cold-chain in
these contexts),11 waning immunity among previously seropro-
tected individuals,12 and impaired immunogenicity to measles
vaccine due to health-related factors known to inﬂuence the
immune response to vaccination, such as malnutrition.13 Addi-
tionally, the reduction in circulating measles virus levels associat-
ed with successful measles control may limit or eliminate the
immune-boosting effect of frequent re-exposure.
Another possible factor in the unusual age distribution could be
the high prevalence of HIV infection in Malawi.14 Several studies
have reported associations between measles antibody concentra-
tion and HIV infection and exposure; for example, infants born to
HIV-infected women have lower levels of measles-speciﬁc
transplacental antibodies (which wane faster), potentially leaving
these infants at greater risk of infection before they receive the
scheduled measles vaccination at 9 months.15–18 Other reports
have shown that HIV infection is associated with greater severity of
measles disease,19 higher mortality from measles,20 and prolonged
measles virus shedding.21
Few studies have addressed the role of HIV infection in measles
infection risk among adults and children after infancy:18,22 one
study concluded that measles vaccine-derived antibodies decline
more rapidly in HIV-infected adults (n = 48);23 a further three
studies reported ﬁnding no difference in measles seropositivity
between HIV-infected adults at different stages of disease
progression (as measured by CD4 count).24–26 A study among
Kenyan adults in Nairobi found no statistical difference in measles
IgG seroprevalence and concentration between HIV-infected and
HIV-uninfected adults, and concluded that reduced immunity
among HIV-infected adults was not a major contributor to measles
resurgence in that country.22
An association between HIV infection and measles susceptibili-
ty in individuals over 18 months of age could have wide-ranging
implications throughout areas of high HIV prevalence in Africa and
Asia that remain at risk for measles outbreaks,10 where achieving
measles control goals may need to include speciﬁc guidance for
HIV-infected individuals. To investigate this possible association,
we assessed measles antibody levels according to HIV status and
CD4 count among individuals presenting at a hospital-based
outpatient clinic in a rural district of southern Malawi.
2. Materials and methods
2.1. Study design, setting, and participants
We investigated the relationship between HIV status (both
serostatus and CD4 count) and measles antibody concentration.
This cross-sectional study was conducted between January and
September 2012 at Chiradzulu District Hospital in Malawi, the
nominal catchment area of which includes all people living within
Malawi’s Chiradzulu District.
A convenience sample of HIV-uninfected participants was
recruited from among individuals who voluntarily presented for
HIV counselling and testing during the study period: all people
who presented and who were subsequently found to be HIV-
uninfected were referred to the study recruiters. Meanwhile, a
convenience sample of HIV-infected participants was recruited
from patients already on HIV treatment and who presented for
follow-up care during the study period: all people who presented
for such care were referred, after their medical consultation, to the
study recruiters.The study recruiters explained the study purpose and design to
all individuals (or their guardians if they were younger than
18 years old) referred to them. Those who gave informed consent
to participate were recruited into the study. Eligibility for
inclusion was restricted to individuals aged 18 months or older
at the time of recruitment to minimize the potential inﬂuence of
maternal antibodies acquired either transplacentally or through
breastfeeding.
2.2. Variables
The primary outcome measure of this study was measles
seroprotection status (seroprotected vs. not seroprotected), and for
this purpose, we set the seroprotected threshold (the antibody
concentration considered protective against disease) at 330 mIU/
ml.27,28 The secondary outcome was measles IgG antibody
concentration among HIV-infected participants only, measured
as a continuous variable.
To explore predictors of measles seroprotection status, the
exposure variable of interest was HIV infection status (HIV-
infected vs. HIV-uninfected), while for measles antibody concen-
tration among HIV-infected participants, the CD4 count was the
exposure variable of interest. Additional predictors, potential
confounders, and effect-modiﬁers included for both outcomes
were age and sex,27 time on highly active antiretroviral therapy
(HAART),18,27,29 and reported measles vaccination and infection
status.1
2.3. Data sources and measurement
Samples of venous blood were collected from each participant
for CD4 counts and measles serology. The manufacturer’s
instructions were followed for all analytical procedures. CD4
counts were determined on site by standard ﬂow cytometry with
Cyﬂow (Partec, Mu¨nster, Germany) analysis within 1–6 h of
specimen collection.
Serum samples were obtained from whole blood and stored at
20 8C at Chiradzulu District Hospital until transfer to the National
Institute for Communicable Diseases in South Africa, where
measles serology was performed. Measles IgG antibody concen-
trations were assessed quantitatively by ELISA (Enzygnost Anti-
Measles Virus IgG; Siemens, Marburg, Germany), using kit-
dependent parameters.
For each participant, we recorded age, sex, reported measles
infection status (ever having had measles), and reported measles
vaccination status (ever having been vaccinated against measles).
The treatment programme identiﬁcation number of HIV-infected
participants was also recorded to enable linking to the HIV
treatment database to include duration of treatment on HAART in
the analyses.
2.4. Bias
In order to limit potential sources of bias, all laboratory staff
were blinded to the HIV status of participants.
2.5. Study size
Obtaining representative samples of hard-to-reach individuals
is a major challenge for epidemiological studies and surveillance.30
Traditional sampling methods often involve very large sample
sizes, which are prohibitive due to operational and cost difﬁculties.
Most importantly, carrying out home-based studies in this context
is hindered by ethical considerations, as individuals may not
disclose their HIV status, if known, to family members and friends.
Like many other studies of this type, we used convenience
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sample size.30 A 10% difference in the proportion of individuals
with protective concentrations of measles antibodies (seroprotec-
tion) between HIV-infected and HIV-uninfected individuals was
considered both realistic and of public health signiﬁcance. Based
on ﬁndings from Zambia,31 we assumed these proportions to be
60% and 70% among HIV-infected and HIV-uninfected individuals,
respectively. Assuming an alpha of 5%, power of 80%, and a
laboratory test error proportion of 5%, we needed to recruit a total
of 1424 individuals to detect this difference.
2.6. Statistical methods
We present the distributions of study participants by recruit-
ment group (HIV infection status), according to age group
(18 months to 17 years, and 18 years), sex, measles seroprotec-
tion status, and median time on HAART.
The association between HIV infection status and measles
seroprotection was explored by ﬁtting a log binomial generalized
linear (logistic regression) model, while linear regression was used
to model the association between HIV infection and log measles
antibody concentration.13,16,32 All regression models were adjust-
ed for the potential risk factors and confounders for IgG
concentration listed above.
As there is no clearly deﬁned IgG threshold for measles
seroprotection, and in order to explore the relationship between
HIV status and possible vaccine failure (deﬁned here as having a
sufﬁcient measles IgG concentration to be classiﬁed as seropositive
but not sufﬁcient to be classiﬁed as seroprotected), a sensitivity
analysis was performed to explore the effect of using a different
IgG threshold on our ﬁndings, using a commonly-deﬁned measles
IgG seropositivity threshold (120 mIU/ml).16,32
Conﬁdence intervals (95% CI) and p-values are presented for all
results.
Data were entered into EpiData 3.1 (EpiData Association,
Odense, Denmark) and cleaned and analysed using R software
version 3.0.3 (R Development Core Team, R Foundation for
Statistical Computing; http://www.r-project.org).
2.7. Ethics statement
This project adhered to the Declaration of Helsinki. The study
protocol received ethical approval from the National Health
Sciences Research Committee of Malawi. The study was explained
to all study participants (or their guardians if they were under the
age of 18 years) in Chichewa, the local language, and all provided
informed consent to participate. The conﬁdentiality of participants
was respected at every stage of this study, and all information wasTable 1
Characteristics of HIV-uninfected and HIV-infected study participants, Chiradzulu Dist
Characteristic HIV-uninfected (%) 
Age group
18 months to 17 years 55 (11.0) 
18 years 445 (89.0) 
Sex
Male 194 (38.9) 
Female 305 (60.9) 
Measles seroprotection statusa
Not seroprotected 52 (10.4) 
Seroprotected 449 (89.6) 
Median IgG (IQR) 2301 (834–4873) 
Time on HAART (n = 1049)
Median number of days (IQR) - 
Total 501 
IQR, interquartile range; HAART, highly active antiretroviral therapy.
a Measles seroprotection deﬁned as IgG antibody concentration 330 mIU/ml.encoded with a non-nominative unique identiﬁcation number.
Participants were free to withdraw from the study at any time, and
all participation was voluntary. Treatment and counselling were
provided free of charge to all participants irrespective of study
participation. We did not collect information on the numbers of
individuals who refused to participate in this speciﬁc study.
3. Results
3.1. Descriptive analysis
One thousand nine hundred and sixty participants were
recruited into the study, of whom 25 were excluded from the
analysis because of quality issues with their blood samples. The
remaining 1935 participants were included in the analyses, of
whom 1434 were HIV-infected and 501 were HIV-uninfected
(Table 1). Nearly two-thirds of participants (n = 1226, 63.4%) were
female. The median age of the participants was 37 years
(interquartile range 29–46 years), and 141 (7.2%) participants
were children (aged 18 months to 17 years). The median age of the
HIV-uninfected participants was 9 years younger than that of the
HIV-infected participants (Figure 1). Information on the duration
of treatment on HAART was available for 1049 (73.2%) HIV-
infected participants.
While there was a clear difference between age groups in the
distribution of the log measles IgG concentration, these were
generally similar according to the other explanatory variables of
interest (Figure 2).
3.2. Main results
More than half (58.9%) of the children and almost all (94.3%) of
the adult participants (those aged 18 years) were seroprotected
against measles (Table 2).
In the unadjusted analyses, HIV status, age, sex, and reported
vaccination status were all signiﬁcantly associated with measles
seroprotection, while reported prior measles infection was not
associated with this outcome (Table 3).
In the multivariate logistic model, age was found to interact
with the association between HIV status and measles seroprotec-
tion (p < 0.001); therefore, we did an age-stratiﬁed analysis of this
association.
Among children, HIV infection (adjusted odds ratio (OR) 0.27,
95% CI 0.10–0.69; p = 0.006) was associated with a decreased odds
of being measles seroprotected (Table 3). However, among adults,
HIV infection was not associated with measles seroprotection.
Among adults, age was associated with an increased odds of being
measles seroprotected (adjusted OR 1.12, 95% CI 1.08–1.15;rict, Malawi, January to September 2012 (N = 1935)
HIV-infected (%) Total
86 (6.0) 141 (7.3)
1347 (94.0) 1792 (92.7)
512 (35.7) 706 (36.5)
921 (64.3) 1226 (63.4)
108 (7.5) 174 (9.0)
1326 (92.5) 1761 (91.0)
2956 (1238–5657) 2793 (1085–5400)
1721 (756–2575) 1721 (756–2575)
1434 1935
Figure 1. Age distribution of HIV-infected and HIV-uninfected study participants,
Chiradzulu District, Malawi, January to September 2012. The dashed lines show the
median ages of each group (N = 1935).
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ated with a lower odds of being measles seroprotected (adjusted
OR 0.49, 95% CI 0.26–0.93; p = 0.030). In both age groups, neither
sex nor reported prior measles infection was signiﬁcantly
associated with measles seroprotection, but this may have been
due to the reduction in sample size in these stratiﬁed analyses.
In the log-linear regression model, neither CD4 count (p = 0.16)
nor time on HAART (p = 0.25) was associated with measles
antibody concentration among HIV-infected participants, while
older age (b = 0.04; p < 0.001) and female sex (b = 0.29, p < 0.001)
were positively associated with increasing measles antibody
concentration.
We performed a sensitivity analysis to explore the effect of
using an alternative IgG concentration on our results. This
alternative threshold did not affect our ﬁndings (Table 3). In
addition, we explored the relationship between vaccine failure
(120 mIU/ml  IgG < 320 mIU/ml) and HIV status, and found that
HIV status was not associated with a likelihood of vaccine failureFigure 2. Distributions of, and median (dashed lines), measles antibody log concentrati
District, Malawi, January to September 2012 (N = 1935).(p = 0.39), but males and younger participants were more likely to
have such intermediate concentrations.
4. Discussion
In this study population, HIV status was associated with
measles seroprotection status among children, but not among
adults. CD4 count was not associated with measles antibody
concentration among HIV-infected individuals. Older age and
female sex were associated both with greater odds of measles
seroprotection and higher measles antibody concentration.
The majority of the study participants were seroprotected
against measles infection, and this was true of both HIV-infected
and uninfected participants. Most participants aged 18 years
were seroprotected against measles, but approximately half the
children aged <18 years were vulnerable to measles infection.
A greater proportion of HIV-uninfected adults were measles
seronegative compared to HIV-infected adults. This may be an
artefact of the recruitment process: as HIV-uninfected participants
were recruited while attending for HIV testing, they may have been
experiencing ill-health at the time of recruitment; they may also
have exhibited other risk factors, or there may have been other
unknown differences between these two groups. As a result, the
HIV-uninfected adults may not be comparable to HIV-infected
adults in terms of their past or current health or health-seeking
behaviour. On the other hand, as HIV-infected participants were
recruited while attending regular treatment sessions, they may
therefore have had more opportunities for vaccination during their
regular clinic visits than their HIV-uninfected study counterparts
at the time of recruitment, particularly as measles vaccination is
recommended following the immune reconstitution that accom-
panies HAART.18,33–36 A decreased likelihood that HIV-infected
children are measles seroprotected (despite potential artefacts
resulting from the recruitment procedure) has been reported
elsewhere, but should be interpreted with caution, as the numberons among the study population, according to baseline characteristics, Chiradzulu
Table 2
Distribution of study participants according to measles seroprotection status and HIV infection status, among children (aged 18 months to 17 years) and adults (aged 18
years), Chiradzulu District, Malawi, January to September 2012 (N = 1935)
Seroprotection statusa Children (n = 141) Adults (n = 1792)
HIV-uninfected (%) HIV-infected (%) HIV-uninfected (%) HIV-infected (%)
Not protected 13 (23.6) 45 (52.3) 39 (8.8) 63 (4.7)
Protected 42 (76.4) 41 (47.7) 406 (91.2) 1284 (95.3)
a Measles seroprotection deﬁned as IgG antibody concentration 330 mIU/ml.
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proportion of the total sample size.
We found that prior vaccination was independently associated
with a lower odds of measles seroprotection, which is counterin-
tuitive, as measles vaccination should boost the immune response.
This ﬁnding is hard to explain, but we suspect that it may have
derived from two possibilities: either from the recruitment
procedure itself and/or poor recall of prior vaccination, which
for many participants would have occurred in their distant past.
The absence of an association between CD4 count and measles
antibody concentration was previously reported among HIV-
infected adults in the USA25 and among HIV-infected Kenyan
children36 and adults.22 Further, the antibody response to measles
vaccine was not associated with CD4 count in HIV-infected
Zambian children.37 However, a low CD4 count was associated
with both a lower measles antibody concentration and a worse
response to revaccination with measles vaccine among HIV-
infected children in Central Africa.38 One study found no difference
in the initial immune response to measles, mumps, and rubella
vaccine between HIV-infected adults on HAART and HIV-uninfect-
ed adults, but reported more rapid waning of these antibodies
among HIV-infected adults, despite high CD4 counts.23 Therefore,
if HIV infection does inﬂuence susceptibility to measles infection
among adults, it may operate through a mechanism unrelated to
CD4 count.
Overall, these results support the idea that ensuring adequate
vaccination coverage may be the most important factor in the
control and elimination of measles.6 We found no evidence that
HIV infection among adults contributed to the risk of measles
infection in this sample, but we did ﬁnd that HIV-infected children
were less likely to be seroprotected against measles infection.
Previously, this had been demonstrated from infancy up to age
36 months,13,37–39 but we report that this may also be true for older
children, up to 17 years old. Our results also suggest that, if HIV
status does contribute to measles infection risk, it may not be due
to low CD4 count.Table 3
Unadjusted and adjusted associations between measles seroprotection and various exp
Exposure variable Unadjusted analysis Adju
Child
OR (95% CI) p-Value OR (
HIV status
HIV-uninfected Ref. Ref. 
HIV-infected 1.42 (1.00–2.01) 0.047 0.27 
Age
Per additional year 1.11 (1.09–1.13) <0.001 1.06 
Sex
Male Ref. Ref. 
Female 1.60 (1.15–2.21) 0.005 1.91
Reported vaccination status
Unvaccinated Ref. Ref. 
Vaccinated 0.45 (0.26–0.79) 0.005 0.49 
Reported infection status
Never infected Ref. Ref. 
Previously infected 1.91 (0.77–4.76) 0.17 2.21
OR, odds ratio; CI, conﬁdence interval.Although protection against measles infection was high among
adults in this sample, the level may be insufﬁcient to prevent
periodic outbreaks.6 Vaccination of HIV-infected adults who are
not seroprotected against measles has been recommended.25 As
approximately 10% of HIV-uninfected adults were also not
seroprotected against measles, revaccination of these vulnerable
adults would provide individual and public health beneﬁts. The
current target age range for supplementary immunization activi-
ties in Sub-Saharan African countries identiﬁed for measles
elimination strategies is 9 months to 14 years; to strengthen the
attainment of elimination goals, the age range could be widened to
include vulnerable older children and young adults. However, such
a strategy would require substantial resources, and would need to
be weighed against other potential interventions.
A large proportion of children were not seroprotected against
measles, and HIV-infected children were at greater risk of having a
sub-protective level of measles antibodies. Current World Health
Organization (WHO) recommendations include the administration
of a supplementary measles vaccination at age 6 months to HIV-
infected infants in addition to the regular Expanded Programme on
Immunization schedule, unless otherwise indicated.40 Our results
suggest that HIV-infected children may be less protected against
measles infection than uninfected members of their cohort at older
ages than previously reported, and this supports the proposal that
measles vaccination should be reinforced for all HIV-infected
children, irrespective of age, by offering at least one further
opportunity for measles vaccination after successful immune
reconstitution with HAART.18,33–36 Furthermore, in such a context,
in which one quarter of HIV-uninfected and half of HIV-infected
children were not seroprotected against measles, we also
recommend offering additional opportunities for measles vacci-
nation for all children, to reduce the risk at both the individual level
(through immunity boosters) and community level (through the
effect of herd immunity).
As antiretroviral therapy becomes more widely available,
thereby increasing the longevity of HIV-infected individuals, theosure variables, Chiradzulu District, Malawi, January to September 2012 (N = 1935)
sted analysis
ren Adults
95% CI) p-Value OR (95% CI) p-Value
Ref.
(0.10–0.69) 0.006 1.08 (0.61–1.93) 0.79
(0.95–1.17) 0.33 1.12 (1.08–1.15) <0.001
Ref.
 (0.88–4.14) 0.10 1.54 (0.94–2.52) 0.09
Ref.
(0.09–2.71) 0.41 0.49 (0.26–0.93) 0.030
Ref.
 (0.37–13.42) 0.39 1.95 (0.56–6.82) 0.29
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vaccine and infection will become increasingly important for
measles control.36,41 This study suggests that HIV-infected
children up to the age of 18 years may be less likely to be
seroprotected against measles, and therefore represent a poten-
tial pool of susceptible individuals who could contribute to
propagating transmission and sustaining outbreaks of measles,
thereby compromising the WHO Expanded Programme on
Immunization. In high HIV prevalence settings, where the control
and elimination of measles is a key public health goal and where a
substantial proportion of the population is aged less than
18 years, vaccination strategies may need to be adapted to
address adequately the additional potential risk posed by this
high-risk section of the population. More population-based
research is needed to elucidate further the age range at which
this risk is elevated.
The principal limitation of this study is that the cross-sectional,
convenience sampling design precludes making causal inferences
between HIV infection status and measles serostatus. In addition,
we recruited study participants from among routine attendees at
Chiradzulu District Hospital, as we could not ethically justify the
recruitment of HIV-uninfected participants who had not them-
selves taken the initiative to ﬁnd out their own HIV status.
Although we considered this appropriate for an explorative,
hypothesis-generating study, this non-population-based conve-
nience sampling method did not permit selection according to
baseline characteristics of the participants in each recruitment
group, and may have introduced various forms of selection bias.
Future research could explore these issues by use of a population-
based recruitment procedure, thereby ensuring greater similarity
in these characteristics between recruitment groups. Population-
based studies of this nature are often prohibitive, but additional
research would be essential in order to provide more robust
evidence.
A limit to the generalizability of our ﬁndings is that fact that we
enrolled only HIV-infected individuals already on HAART, and
whose immune system has likely been reconstituted and who have
subsequently been offered additional opportunities for measles
vaccination. These ﬁndings may therefore apply only to a narrow
range of circumstances in Sub-Saharan Africa, i.e. where access to
HIV treatment is high.
Because of the recruitment procedure, few infants and young
children were recruited into this study, as children aged <18
months were excluded, and relatively few young children either
present for HIV testing or are on HIV treatment. Young children are
the most vulnerable to measles infection, and it is among these
individuals that HIV status has been reported to inﬂuence measles
antibody concentrations through a variety of mechanisms.29,31,42
However, our primary objective was to explore the relationship of
HIV status and measles seroprotection among older children and
young adults, among whom the attack rate of the 2010 measles
epidemic was surprisingly high and for whom research on the
impact of HIV on susceptibility to measles has been identiﬁed as a
priority.10
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